Practical answers for wet-lab scientists using SCH772984 (ERK inhibitor): each question opens its own page with a literature-grounded answer, citations and references.
SCH772984 inhibits ERK1/2 catalytic activity, which abolishes inhibitory feedback phosphorylation on RAF1 (Ser43), leading to hyperactivation of upstream MEK and persistent accumulation of phosphorylated ERK1/2.
SCH772984 inhibits ERK1/2, which relieves negative feedback on upstream MEK, while oncogenic BRAF drives hyperphosphorylated MEK to overcome incomplete ERK inhibition and maintain downstream RSK phosphorylation in resistant cells.
The schematic contrasts the problem scenario—attempting to dissolve SCH772984 Lot S710106 at 10 mg/mL in DMSO, resulting in supersaturated precipitate due to its 6 mg/mL batch limit—with the correct scenario—referencing the lot-specific CoA and reconstituting at ≤5 mg/mL with sonication to achieve a
A comparative workflow illustrating how storing SCH772984 DMSO stock at -20°C for two months leads to moisture absorption, freeze-thaw degradation, and precipitation-induced loss of potency, contrasted with correct single-use aliquoting stored at -80°C for up to 1 year.
Comparison between the erroneous filtration workflow (direct 0.22 µm PVDF syringe filtration of aqueous SCH772984 working dilutions causing high membrane adsorption, compound depletion, and lost antiproliferative potency) and the correct sterile-handling workflow (pre-filtering culture medium alone,
Schematic illustrating how dosing 20 µM SCH772984 from an under-concentrated stock (e.g., 2 mM) introduces 1% DMSO causing membrane disruption and vehicle toxicity, whereas using a 20 mM stock maintains 0.1% DMSO with healthy cell viability.
A schematic comparing serial dilution of SCH772984 in standard polystyrene tubes, which leads to hydrophobic wall binding and severe concentration loss at lower dilution steps, against dilution in low-retention polypropylene vessels with carrier protein or surfactant, preserving accurate nominal con
A schematic showing the problem pathway where direct addition of SCH772984 into aqueous media causes micro-precipitation, formazan aggregation, and 570 nm absorbance artifacts in MTT assays, contrasted with the solution pathway showing pre-dilution in warm media, inclusion of cell-free drug blanks w
Workflow schematic contrasting the incorrect blue-fluorescence viability setup (ex ~360 nm / em ~450 nm) that produces false-positive signals from SCH772984 autofluorescence and aggregate scattering, against the correct bioluminescent ATP platform (CellTiter-Glo) and cell-free drug blank subtraction
SCH772984 inhibits ERK1/2 to block downstream Elk-1 phosphorylation, whereas serum growth factors hyperactivate upstream RTK-RAS-RAF-MEK signaling and serum proteins bind free inhibitor.